FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Shearer

Research Profile

Disorders

Geographic Areas

Chemicals & Drugs

Objects

Prisons

Activities & Behaviors

Living Beings

Prisoners

Concepts & Ideas

Co-author Network

Publications

TOP 3
Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein
Cost effectiveness of oromucosal cannabis-based medicine (sativex®) for spasticity in multiple sclerosis.
James Shearer; Carl E Counsell; Colin Green; John P Zajicek
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.
Colin Green; Craig W Ritchie; James Shearer; John P Zajicek
Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Shearer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein
Cost effectiveness of oromucosal cannabis-based medicine (sativex®) for spasticity in multiple sclerosis.
PharmacoEconomics 2012;30(12):1157-71.
2012: James Shearer; Carl E Counsell; Colin Green; John P Zajicek
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.
Journal of neurology 2012;259(3):462-8.
2011: Colin Green; Craig W Ritchie; James Shearer; John P Zajicek
Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2011;14(5):621-30.
2011: James Shearer; Carl E Counsell; Colin Green; John P Zajicek
The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.
Applied health economics and health policy 2011;9(4):243-58.
2010: James Shearer; Marian Shanahan; Shane Darke; Craig Rodgers; Ingrid van Beek; Rebecca McKetin; Richard P Mattick
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
Drug and alcohol review 2010;29(3):235-42.
2009: James Shearer; Shane Darke; Craig Rodgers; Tim Slade; Ingrid van Beek; John Lewis; Donna Brady; Rebecca McKetin; Richard P Mattick; Alex Wodak
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
Addiction (Abingdon, England) 2009;104(2):224-33.
2008: James Shearer
The principles of agonist pharmacotherapy for psychostimulant dependence.
Drug and alcohol review 2008;27(3):301-8.
2007: James Shearer; Jennifer Johnston; Craig L Fry; Sharlene Kaye; Paul Dillon; Paul Dietze; Linette Collins
Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia.
Drug and alcohol review 2007;26(5):537-43.
2007: James Shearer
Psychosocial approaches to psychostimulant dependence: a systematic review.
Journal of substance abuse treatment 2007;32(1):41-52.
2006: James Shearer; Marian Shanahan
Cost effectiveness analysis of smoking cessation interventions.
Australian and New Zealand journal of public health 2006;30(5):428-34.
2006: Emma Warren; Rosalie Viney; James Shearer; Marian Shanahan; Alex Wodak; Kate Dolan
Value for money in drug treatment: economic evaluation of prison methadone.
Drug and alcohol dependence 2006;84(2):160-6.
2006: James Shearer; Bethany White; Stuart Gilmour; Alex Wodak; Kate A Dolan
Hair analysis underestimates heroin use in prisoners.
Drug and alcohol review 2006;25(5):425-31.
2005: Kate A Dolan; James Shearer; Bethany White; Jialun Zhou; John Kaldor; Alex Wodak
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.
Addiction (Abingdon, England) 2005;100(6):820-8.
2004: Kate Dolan; Nicole Clement; David Rouen; Vaughan Rees; James Shearer; Alex Wodak
Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs?
Drug and alcohol review 2004;23(3):281-6.
2004: James Shearer; Linda R Gowing
Pharmacotherapies for problematic psychostimulant use: a review of current research.
Drug and alcohol review 2004;23(2):203-11.
2004: Kate Dolan; David Lowe; James Shearer
Evaluation of the condom distribution program in New South Wales Prisons, Australia.
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 2004;32(1):124-8.
2003: Kate A Dolan; James Shearer; Margaret MacDonald; Richard P Mattick; Wayne Hall; Alex Wodak
A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.
Drug and alcohol dependence 2003;72(1):59-65.
2003: James Shearer; Alex Wodak; Ingrid van Beek; Richard P Mattick; John Lewis
Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.
Addiction (Abingdon, England) 2003;98(8):1137-41.
2002: James Shearer; John Sherman; Alex Wodak; Ingrid van Beek
Substitution therapy for amphetamine users.
Drug and alcohol review 2002;21(2):179-85.
2001: James Shearer; Alex Wodak; Richard P Mattick; Ingrid van Beek; J Lewis; Wayne Hall; Kate Dolan
Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence.
Addiction (Abingdon, England) 2001;96(9):1289-96.